Accelerated Pharma (Accelerated Pharma) EBITDA Margin % : 0.00% (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Accelerated Pharma's EBITDA for the three months ended in Mar. 2017 was $-0.36 Mil. Accelerated Pharma's Revenue for the three months ended in Mar. 2017 was $0.00 Mil. Therefore, Accelerated Pharma's EBITDA margin for the quarter that ended in Mar. 2017 was 0.00%.

Accelerated Pharma EBITDA Margin % Historical Data

The historical data trend for Accelerated Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma EBITDA Margin % Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

EBITDA Margin %

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
EBITDA Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's EBITDA Margin % falls into.

Accelerated Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Accelerated Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2016 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2016 )	/	Revenue (A: Dec. 2016 )
	=	-3.091	/	0
	=	%

Accelerated Pharma's EBITDA Margin % for the quarter that ended in Mar. 2017 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2017 )	/	Revenue (Q: Mar. 2017 )
	=	-0.36	/	0
	=	%

Accelerated Pharma (NAS:ACCP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Accelerated Pharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines